WBC
SAGE

Westpac Banking Corp’s Sage Therapeutics SAGE Stock Holding History

Westpac Banking Corp’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-44,150
Closed -$1.27M – 873
2020
Q1 		$1.27M Sell
44,150
-2,900
-6% -$168K 0.02% 541
2019
Q4 		$3.4M Sell
47,050
-8,400
-15% -$1.03M 0.04% 452
2019
Q3 		$7.78M Sell
55,450
-5,578
-9% -$933K 0.11% 268
2019
Q2 		$11.2M Sell
61,028
-6,926
-10% -$1.18M 0.17% 157
2019
Q1 		$10.8M Sell
67,954
-14,136
-17% -$2.05M 0.18% 162
2018
Q4 		$7.86M Buy
82,090
+917
+1% +$105K 0.13% 208
2018
Q3 		$11.5M Sell
81,173
-13,300
-14% -$2.05M 0.2% 147
2018
Q2 		$14.8M Buy
94,473
+5,847
+7% +$918K 0.28% 105
2018
Q1 		$14.3M Buy
88,626
+16,687
+23% +$2.83M 0.29% 102
2017
Q4 		$11.8M Buy
71,939
+29,130
+68% +$2.82M 0.27% 108
2017
Q3 		$2.67M Buy
+42,809
New +$3.36M 0.06% 364

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Westpac Banking Corp's SAGE Position: Q2 2020 in Review

Westpac Banking Corp sold out of Sage Therapeutics (SAGE) in Q2 2020, closing a stake of 44,150 shares — an estimated $1.27M sold.

Westpac Banking Corp first reported a position in SAGE in Q3 2017 and held it in 11 quarters. The position peaked at $14.8M in Q2 2018. 217 funds tracked by Wall St. Rank hold SAGE as of Q2 2020.

  • Westpac Banking Corp reported no remaining Sage Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Westpac Banking Corp sold 44,150 Sage Therapeutics shares in Q2 2020, an estimated $1.27M.
  • Westpac Banking Corp first reported a position in Sage Therapeutics in Q3 2017 and held it in 11 quarters.
  • Westpac Banking Corp's Sage Therapeutics position peaked at $14.8M in Q2 2018.
  • 217 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2020.

Based on Westpac Banking Corp's 13F filing for Q2 2020, filed 12 Aug 2020.